TW202135810A - 組合 - Google Patents

組合 Download PDF

Info

Publication number
TW202135810A
TW202135810A TW109145166A TW109145166A TW202135810A TW 202135810 A TW202135810 A TW 202135810A TW 109145166 A TW109145166 A TW 109145166A TW 109145166 A TW109145166 A TW 109145166A TW 202135810 A TW202135810 A TW 202135810A
Authority
TW
Taiwan
Prior art keywords
cancer
optionally substituted
group
pharmaceutically acceptable
compound
Prior art date
Application number
TW109145166A
Other languages
English (en)
Chinese (zh)
Inventor
亞玫德 亞迪 沙曼塔
馬健會
佳莉 李
琴華 黃
薩伊 葛迦納 赫格德
凱文 杜安 班納
費南多 杜奈特
Original Assignee
美商瑞卡瑞恩Ｉｐ控股有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商瑞卡瑞恩Ｉｐ控股有限責任公司 filed Critical 美商瑞卡瑞恩Ｉｐ控股有限責任公司
Publication of TW202135810A publication Critical patent/TW202135810A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
  • Glass Compositions (AREA)
TW109145166A 2019-12-20 2020-12-18 組合 TW202135810A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962952042P 2019-12-20 2019-12-20
US62/952,042 2019-12-20
US202063009754P 2020-04-14 2020-04-14
US63/009,754 2020-04-14

Publications (1)

Publication Number Publication Date
TW202135810A true TW202135810A (zh) 2021-10-01

Family

ID=76478099

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109145166A TW202135810A (zh) 2019-12-20 2020-12-18 組合

Country Status (12)

Country Link
US (1) US20230042653A1 (enExample)
EP (1) EP4069224A4 (enExample)
JP (1) JP2023507799A (enExample)
KR (1) KR20220119428A (enExample)
CN (1) CN115103673A (enExample)
AU (1) AU2020408698A1 (enExample)
BR (1) BR112022012286A2 (enExample)
CA (1) CA3165477A1 (enExample)
IL (1) IL294084A (enExample)
MX (1) MX2022007624A (enExample)
TW (1) TW202135810A (enExample)
WO (1) WO2021127046A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202543650A (zh) 2024-03-08 2025-11-16 美商海爾達醫療運營公司 異雙官能化合物及其在治療疾病中之用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5411847B2 (ja) * 2007-04-25 2014-02-12 Ｍｓｄ株式会社 Ｗｅｅｌキナーゼインヒビターとしてのジヒドロピラゾロピリミジノン誘導体の多形
CN101970440A (zh) * 2007-11-28 2011-02-09 先灵公司 作为蛋白激酶抑制剂的2-氟吡唑并[1，5-a]嘧啶类
EP2477628B1 (en) * 2009-09-15 2014-08-20 Merck Sharp & Dohme Corp. Preparation of crystalline hemihydrate forms of dihydropyrazolopyrimidinone
RS56680B1 (sr) * 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
WO2016146591A1 (en) * 2015-03-16 2016-09-22 Astrazeneca Ab Combination treatment
JP6692423B2 (ja) * 2015-11-01 2020-05-13 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレイト Ｗｅｅ１キナーゼ阻害剤、並びにそれを作製及び使用する方法
KR20220071293A (ko) * 2016-04-01 2022-05-31 리커리엄 아이피 홀딩스, 엘엘씨 에스트로겐 수용체 조절제
US11932650B2 (en) * 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
SG11202003974XA (en) * 2017-11-01 2020-05-28 Shijiazhuang Sagacity New Drug Development Co Ltd Macrocyclic compound serving as weel inhibitor and applications thereof
KR20220044528A (ko) * 2019-08-06 2022-04-08 리커리엄 아이피 홀딩스, 엘엘씨 돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제

Also Published As

Publication number Publication date
AU2020408698A1 (en) 2022-07-14
BR112022012286A2 (pt) 2022-08-30
KR20220119428A (ko) 2022-08-29
WO2021127046A1 (en) 2021-06-24
CN115103673A (zh) 2022-09-23
US20230042653A1 (en) 2023-02-09
CA3165477A1 (en) 2021-06-24
MX2022007624A (es) 2022-08-16
IL294084A (en) 2022-08-01
EP4069224A1 (en) 2022-10-12
EP4069224A4 (en) 2023-12-20
JP2023507799A (ja) 2023-02-27

Similar Documents

Publication Publication Date Title
TW202142234A (zh) 組合
TW202135809A (zh) 組合
TW202135818A (zh) 組合
TW202135819A (zh) 組合
TW202132299A (zh) 組合
TW202135810A (zh) 組合
TW202135807A (zh) 組合
TW202135814A (zh) 組合
TW202135808A (zh) 組合
RU2845443C1 (ru) Комбинации